The study will evaluate ReActiv8 compared to a patient’s optimal medical management, according to a news release. ReActiv8 is designed to help patients with intractable chronic low back pain.
The trial will be done at 25 centers in the U.S.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
